Blue Cross Blue Shield · Arni Entresto · US health-plan appeal rights

Arni Entresto denied as not FDA-approved for this use by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Arni Entresto denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for arni entresto are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS medical policy / Anthem clinical guideline — Entresto (Sacubitril/Valsartan)

The Blue Cross Blue Shield angle on Arni Entresto

## Why BCBS Denied Entresto as "Not FDA-Approved" — and Why This Is Almost Certainly Wrong

Entresto (sacubitril/valsartan) has held FDA approval since 2015 and has an additional approved indication added subsequently. A "not FDA-approved" denial for Entresto in an on-label use is one of the most straightforwardly rebuttable denial types, because the FDA approval is a public, verifiable fact. This denial most commonly reflects one of three errors: (1) a coding mistake on the claim, (2) the use being for an indication not yet in BCBS's medical policy even though the FDA has approved it, or (3) an outdated BCBS medical policy that has not been updated to reflect the current FDA label.

## Why This Is Appealable

FDA approval status is not a matter of clinical judgment — it is documented in the FDA-approved prescribing information, available publicly on DailyMed. If the use is on-label, the denial has no factual basis and should be reversed on internal appeal with minimal documentation. If the use is for a newer FDA-approved indication not yet in BCBS's policy, the appeal should present the FDA approval alongside the current prescribing information and request that BCBS apply the current label rather than an outdated policy.

## Federal Appeal Framework

Internal appeal: File within the deadline on the denial letter. Attach a printed copy of the current FDA-approved prescribing information (from DailyMed) and a brief prescriber letter confirming on-label use. This is often resolved at Level 1.
ACA §2719 external review: Available if the internal appeal fails. IRO reviewers will have no difficulty recognizing an FDA-approved therapy. Window is approximately four months from the final internal denial.
Expedited review: Available for urgent cardiac situations.
ERISA §503: Requires BCBS to disclose the specific provision of its policy used to deny, and to conduct a full-and-fair review. If the policy is outdated relative to the FDA label, that discrepancy should be raised explicitly.

## What to Gather

FDA prescribing information: Print the current full prescribing information from DailyMed (dailymed.nlm.nih.gov) showing the approved indication(s) and approval date.
Claim and coding review: Confirm with the prescribing provider's billing office that the diagnosis code and procedure/drug code on the claim accurately reflect the FDA-labeled indication.
Prescriber cover letter: A brief letter from the treating cardiologist confirming that Entresto was prescribed within its FDA-approved indication.
BCBS policy copy: Obtain BCBS's current medical policy for Entresto to identify whether the policy language is inconsistent with the current FDA label.

## Criteria-Mapping Structure

In the appeal letter, quote the specific "not FDA-approved" language from the denial notice, then directly refute it by citing the FDA approval date and indication from the prescribing information. If BCBS's policy appears outdated, state that explicitly and ask the reviewer to apply the current FDA label.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Arni Entresto

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.